United States - English - NLM (National Library of Medicine)

a-s medication solutions - choriogonadotropin alfa (unii: 6413w06wr3) (choriogonadotropin alfa - unii:6413w06wr3) - hcg has not been demonstrated to be effective adjunctive therapy in the treatment of obesity. there is no substantial evidence that it increases weight loss beyond that resulting from caloric restriction, that it causes a more attractive or “normal” distribution of fat, or that it decreases the hunger and discomfort associated with calorie-restricted diets. - prepubertal cryptorchidism not due to anatomical obstruction. in general, hcg is thought to induce testicular descent in situations when descent would have occurred at puberty. hcg thus may help predict whether or not orchiopexy will be needed in the future. although, in some cases, descent following hcg administration is permanent, in most cases, the response is temporary. therapy is usually instituted in children between the ages of 4 and 9. - selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males. - induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately treated with human gonadotropins. - prior hypersensitivity reactions to human gonadotropins, including hcg, or any of the excipients (see adverse reactions). - high serum fsh, indicating primary gonadal failure in women. - presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders). - tumors of the hypothalamus or pituitary gland and ovary, breast, or uterus in females and breast or prostate in males. - malformations of the reproductive organs incompatible with pregnancy. - fibroid tumors of the uterus incompatible with pregnancy. - abnormal vaginal bleeding of undetermined origin.

Canada - English - Health Canada

emd serono, a division of emd inc., canada - chorionic gonadotropin; water - kit - 10000unit; 10ml - chorionic gonadotropin 10000unit; water 10ml - gonadotropins and antigonadotropins

Canada - English - Health Canada

organon canada inc. - chorionic gonadotropin - kit - 10000unit - chorionic gonadotropin 10000unit - gonadotropins and antigonadotropins

Ireland - English - HPRA (Health Products Regulatory Authority)

ipsen pharmaceuticals limited - triptorelin - powder and solvent for suspension for injection - 11.25 milligram(s) - gonadotropin releasing hormone analogues; triptorelin

Ireland - English - HPRA (Health Products Regulatory Authority)

ipsen pharmaceuticals limited - triptorelin - powder and solvent for suspension for injection - 3 milligram(s) - gonadotropin releasing hormone analogues; triptorelin

Singapore - English - HSA (Health Sciences Authority)

merck pte. ltd. - choriogonadotropin alfa - injection, solution - 250 mcg - choriogonadotropin alfa 250 mcg

Ireland - English - HPRA (Health Products Regulatory Authority)

ipsen pharmaceuticals limited - triptorelin pamoate - powder and solvent for prolonged-release suspension for injection - 22.5 milligram(s) - gonadotropin releasing hormone analogues; triptorelin

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

merck sdn. bhd. - choriogonadotropin alfa -

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck serono ltd - choriogonadotropin alfa - solution for injection - 500microgram/1ml

Ireland - English - HPRA (Health Products Regulatory Authority)

mercury pharmaceuticals ltd - leuprorelin acetate - powder and solvent for suspension for injection - 3.75 milligram(s) - gonadotropin releasing hormone analogues; leuprorelin - endocrine therapy. hormones and related agents. gonadotropin-releasing hormones analogues - it is indicated for palliative treatment of locally advanced or metastatic prostate cancer